TUSTIN, CA--(Marketwire - August 19, 2011) - Radient Pharmaceuticals Corporation “the Company” or “Radient” (OTCQX: RXPC) (PINKSHEETS: RXPC), a developer and marketer of In Vitro Diagnostic (IVD) cancer tests, today announced the results from its annual shareholder meeting.
The following three resolutions passed:
1) Class I Directors, Douglas MacLellan and Minghui Jia were reelected.
2) Shareholders approved an increase in the authorized number of shares of the Company’s Common Stock from 200 million to 750 million.
3) KMJ Corbin & Company was re-appointed as the Company’s independent accountants to audit Radient’s financial statements for the fiscal year ended December 31, 2011.
For additional information on Radient Pharmaceuticals Corporation and its products visit: www.radient-pharma.com or e-mail info@radient-pharma.com. For Investor Relations contact Dilek Mir at: ir@radient-pharma.com or 714-881-0244.
The following table is intended to provide the latest information on Radient’s business metrics.
---------------------------------------------------------------------------- RPC’s Business Metrics ---------------------------------------------------------------------------- Cash on hand: $720,000* *Approximate amount as of August 19, 2011 ---------------------------------------------------------------------------- Shares Outstanding: 198 million* *Approximate number as of August 19, 2011 750 million shares to be authorized. ---------------------------------------------------------------------------- Outstanding Warrants & Options: 111 million* *Approximate number as of August 19, 2011 ----------------------------------------------------------------------------
About Radient Pharmaceuticals:
Headquartered in Tustin, California, Radient Pharmaceuticals Corporation is dedicated to saving lives and money for patients and global healthcare systems through the deployment of its FDA-cleared In Vitro Diagnostic Onko-Sure® cancer test kit for colorectal cancer treatment and recurrence monitoring. The Company’s focus is on the discovery, development and commercialization of unique high-value diagnostic tests that will help physicians answer important clinical questions related to early disease state detection, treatment strategy, and the monitoring of disease progression or recurrence. To learn more about our company, products, and potentially life-saving cancer test, visit www.radient-pharma.com.
Forward-Looking Statements:
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company’s operations, markets, services, products, and prices. With respect to Radient Pharmaceuticals Corporation, except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.
Digg this 
Bookmark with del.icio.us 
Add to Newsvine
Technorati: in vitro diagnostics oncology cancer investors shareholder meeting proxy
